Administration of berberine leads to remission of metabolic syndrome and decreases in waist circumference, SBP, triglycerides, and total insulin secretion, with an increase in insulin sensitivity.
Aim: To evaluate the effect of pomegranate juice on insulin secretion and sensitivity in patients with obesity. Methods: A randomized, double-blind, placebo-controlled clinical trial was carried out in 20 obese, adult volunteer subjects. After random allocation of the intervention, 10 patients received 120 ml of pomegranate juice or placebo while in a fasted state for 1 month. Glucose, uric acid, creatinine, lipid profile, and insulin were measured at baseline, and glucose and insulin were also measured at 30, 60, 90, and 120 min. The area under the curve of glucose and insulin, total insulin secretion, and insulin sensitivity was calculated. Results: There was a significant increase in weight, body mass index, and fat mass in the placebo group after the intervention. Insulin secretion and insulin sensitivity were not modified with administration of pomegranate juice. There was a significant difference in changes from baseline in fat mass between groups (1.1 ± 1.1% vs. –1.4 ± 3.0%, p = 0.010; placebo and pomegranate groups, respectively). Conclusion: Pomegranate juice administration for 1 month did not modify insulin secretion and sensitivity in patients with obesity; however, the natural evolution to increased weight and adiposity was halted.
AEP's high-reliability and moderate-validity results with regard to clinical judgement positions it as a useful instrument for appropriate hospitalization screening in elderly patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.